BETA - What are antibody drug conjugates (2026)

This video provides a comprehensive overview of antibody-drug conjugates (ADCs), a rapidly evolving and targeted treatment approach for blood cancers. It explains how ADCs combine a monoclonal antibody with a chemotherapy drug through a specialized linker, allowing treatment to be delivered directly to cancer cells with greater precision.

The video walks through the three key components of ADCs—the antibody, the cytotoxic drug, and the linker—and describes how they work together. Once the antibody binds to a specific marker on a cancer cell, the ADC is taken inside the cell, where the linker breaks down and releases the chemotherapy payload to destroy the tumor from within. This targeted delivery allows for lower doses of chemotherapy and may reduce many of the broader side effects seen with traditional treatments.

Viewers also learn about the different cancer targets used in ADC therapy across conditions like multiple myeloma, leukemia, lymphoma, and even some solid tumors. The video covers how ADCs are administered, typically through IV infusion on a scheduled basis, and explains that they do not usually require step-up dosing like some other immunotherapies.

In addition, the video outlines common side effects, including low blood counts and gastrointestinal symptoms, as well as drug-specific toxicities that vary depending on the chemotherapy payload. It also discusses infusion-related reactions and how they are generally mild and manageable.

Finally, the video explores how ADCs can be used alone or in combination with other treatments, and clarifies their dual role as both immunotherapy and chemotherapy. Overall, it highlights how ADCs offer a more precise and often better-tolerated way to treat cancer by targeting tumor cells while sparing much of the surrounding healthy tissue.